Romidepsin, sold under the brand name Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works as a potent histone deacetylase inhibitor that preferentially targets Class I HDACs; the molecule is a cyclic depsipeptide containing a disulfide linkage that is reduced intracellularly to release a thiol species which coordinates the catalytic zinc ion in HDAC active sites. Inhibition of HDAC activity increases acetylation of histone and non-histone proteins, alters chromatin structure and gene expression, and triggers cell cycle arrest and apoptosis in sensitive malignant T cells. The drug is formulated for intravenous administration, undergoes peptide-like metabolic transformations and oxidative modifications, and is monitored in development and quality control by LC-MS, HPLC with UV detection, and stability-indicating assays to characterize potency, degradation pathways and pharmacokinetic behavior.
Parent: Romidepsin
Routine quality control for romidepsin and finished Dosage Form typically monitors related substances including the reduced thiol form, S-oxidized species (sulfoxide), hydrolytic ring-opened products, N-dealkylated or desmethyl variants, and low-level dimerization or adducts; these are characterized by LC-MS and HPLC. Typical specification ranges used in development and batch release practice keep individual unidentified impurities generally below 0.10 to 0.20 percent by area and total impurities below approximately 1.0 percent, with known degradants assigned specific acceptance limits when toxicology or activity profiles require tighter control. Residual solvents and elemental impurities are controlled to ICH-guideline levels, and stability studies define shelf-life limits for each related compound under recommended storage conditions.
Romidepsin is classified as a targeted epigenetic anticancer agent rather than a conventional cytotoxic chemotherapy or an immune checkpoint immunotherapy; it is an HDAC inhibitor that modifies chromatin and gene expression to induce apoptosis and growth arrest in malignant T cells.
Romidepsin has not been universally withdrawn; there have been occasional supply interruptions, label updates and regulatory reviews related to safety monitoring or manufacturing changes, but the approved product Istodax remains available in many jurisdictions under regulatory oversight rather than being permanently removed.
Common adverse effects include nausea, vomiting, fatigue, anorexia, thrombocytopenia, neutropenia, anemia and infusion-related reactions; laboratory abnormalities such as hypokalemia, hypomagnesemia and liver enzyme elevations can occur. Cardiac effects including ECG changes and potential QT interval prolongation have been reported, so cardiac monitoring and electrolyte management are part of clinical use. Serious infections and sepsis have been observed in patients with prolonged cytopenias.
Romidepsin functions as an HDAC inhibitor whose disulfide bond is reduced intracellularly to produce an active thiol that coordinates the zinc ion in the catalytic pocket of HDAC enzymes, leading to inhibition of deacetylase activity. The resulting increase in acetylated histones and regulatory proteins alters transcriptional programs, promotes expression of tumor suppressor genes, disrupts cell cycle regulation and induces apoptosis and differentiation in susceptible lymphoma cells.
